Hepatic intra-arterial and systemic chemotherapy followed by maintenance therapy for the treatment of cholangiocarcinoma. (April 2017)

• Record Type: Journal Article
• Authors: Fiorentini, Giammaria; Mambrini, Andrea; Sarti, Donatella; Cantore, Maurizio; Mulazzani, Luca; Mattioli, Gian Maria; Guadagni, Stefano
• Is Part Of: Hepatic oncology. Volume 4:Number 2(2017)
• Page Start: 45
• Page End: 53
• Publication Date: 2017-04
• Subjects: biliary tract cancer -- cholangiocarcinoma -- intra-arterial chemotherapy -- tumor response; Liver -- Cancer -- Periodicals; 616.99436005
• DOI: 10.2217/hep-2017-0001
• Languages: English
• ISSNs: 2045-0923

Abstract

Aim: The aim is to report clinical outcomes of hepatic intra-arterial (IACHT) and systemic chemotherapy (SCHT), followed by gemcitabine-based maintenance therapy (maintenance), for the treatment of relapsed or unresectable cholangiocarcinoma.Patients & methods: In this retrospective observational study, 145 cholangiocarcinoma patients were treated with Epirubicin-Cisplatin as IACHT associated with Capecitabine or 5-fluorouracil as SCHT. Maintenance was performed with gemcitabine-based schedule. Toxicity was assessed with NCI-CTCAE and tumor response with RECIST 1.1.Results: Tumor response was complete in 1%, partial in 20%, stable disease in 48% and progression in 31% of patients (3 months after therapy). The most frequent adverse events were: anemia (24%), nausea and vomiting (33%), alopecia (60%).Conclusion: Cholangiocarcinoma patients may benefit from IAHCT-SCHT. Maintenance may prolong clinical benefits. ClinicalTrials.gov registry Identifier: NCT01920503.